Home  »  Trendy Stocks   »  Autolus Therapeutics plc (AUTL) stock is soaring i...

Autolus Therapeutics plc (AUTL) stock is soaring in the premarket: Here’s Why

Shares of the Autolus Therapeutics plc (AUTL) stock soared in the premarket today on November 8, 2021. The stock became bullish after the announcement of a strategic collaboration and financing agreement with BlackStone Life Sciences. AUTL stock price saw a surge of 26.80% to reach $7.05 a share at the time of this writing. The stock was gloomy in the previous trade and went down by 1.59% at closing. Let’s discuss more this stock.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Autolus Therapeutics plc is the biopharmaceutical stock that is focused to treat cancer diseases via the development of T cell therapies. The stock has a current market value of $405.43 million and 440,189 average trading volume.

BlackStone to invest in AUTL stock:

AUTL stock recently announced that it has signed a strategic collaboration and financing agreement with BlackStone Life sciences pursuant to which the latter will invest up to $250 million in the former. This funding will support the advanced development of CD19 CAR T cell investigational therapy product candidate of AUTL stock. The funding will also help Autolus stock in the next generation product therapies of obe-cel in B-cell malignancies.

According to the agreement, BlackStone will invest $150 million as product financing to support the development as well as commercialization of obe-cel development. $50 million will be payable upon the closing of the transaction and the rest of the amount will be payable based on certain developments and regulatory achievements. BlackStone will buy $100 million American Depository Shares of AUTL stock in a private placement subject to customary closing conditions. In connection with the agreement, BlackStone now has a right to nominate the board member of Autolus stock.

Financial View of AUTL stock:

According to third-quarter 2021 financial results, Autolus stock spent $40.4 million in operating expenses in the three months ended September 30, 2021. This compares to net operating expenses of $42.7 million in the same period of the previous year. Research and development expenses were $32.3 million and general and administrative expenses were $8.3 million in the third quarter of 2021. AUTL stock suffered a net loss of $34.0 million in the third quarter of 2021 as compared to $37.3 million for the same tenure of the previous year. By the end of the third quarter, AUTL stock had $173.1 million total in cash as compared to $216.4 million by the end of the second quarter of 2021.

Wrap Up:

AUTL stock has captivated the attention of investors after the announcement of its strategic collaboration and financing agreement with BlackStone. The financing from BlackStone is a good sign for AUTL stock in terms of its clinical developments.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts